New research (the Ver-A-T1D trial) presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15–19 September) shows that slow-release (SR) verapamil (360mg ...
Now UAB researchers, led by Guanlan Xu, Ph.D., and Shalev drilled down further into the mechanism underlying verapamil’s beneficial effect. In a paper published in Diabetes, they show that, in Type 1 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with new-onset type 1 diabetes receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback